TLR4 and cancer: MPLA is a TLR4 agonist modified from lipid A, the biologically active part of Gram-negative bacterial LPS endotoxin; compared to LPS, MPLA exerts similar immunostimulatory activity but with reduced toxicity and has been approved by the FDA to use against cancer-causing HPV [77,176,177].